EXEL..$7.73 Hearing that the FDA is not giving them a SPA for their CABO drug & Ph III study. That is a big negative for investors as it increases risk in the study. SPA's are essential now especially when looking at defining clinical endpoints in a study.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.